<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; CRA</title>
	<atom:link href="http://www.stockbloghub.com/tag/cra/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(DGX) Quest Diagnostics Expedites Celera Acquisition</title>
		<link>http://www.stockbloghub.com/2011/04/15/dgx-quest-diagnostics-expedites-celera-acquisition/71625</link>
		<comments>http://www.stockbloghub.com/2011/04/15/dgx-quest-diagnostics-expedites-celera-acquisition/71625#comments</comments>
		<pubDate>Fri, 15 Apr 2011 17:01:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71625</guid>
		<description><![CDATA[Leading diagnostics player, Quest Diagnostics (DGX) took a step forward toward the proposed acquisition of Celera Corporation (CRA). The company recently announced that the waiting period under the HSR Act has expired, though some other conditions are yet to be met. The tender offer to acquire the shares of Celera is supposed to close on April 25, 2011, unless extended further. Last month, Quest decided to acquire Celera for $8 per share, through which the company plans to strengthen its footing in molecular diagnostics discovery and development. Celera’s proprietary genetic tests, pipeline of biomarkers, along with esoteric cardiovascular test, offered by Berkeley HeartLab should drive Quest’s revenues. Celera, with revenues of $128 million in 2010, is expected to add just over 1% to Quest’s 2011 revenue growth. The transaction, to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/15/dgx-quest-diagnostics-expedites-celera-acquisition/71625/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRA) Celera Corpoation and Abbott Laboratories Sign Deal</title>
		<link>http://www.stockbloghub.com/2010/09/23/cra-celera-corpoation-and-abbott-laboratories-sign-deal/52551</link>
		<comments>http://www.stockbloghub.com/2010/09/23/cra-celera-corpoation-and-abbott-laboratories-sign-deal/52551#comments</comments>
		<pubDate>Thu, 23 Sep 2010 15:11:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52551</guid>
		<description><![CDATA[Recently, Celera Corporation (CRA) has signed a four-year distribution agreement with Abbott Laboratories (ABT) to market Celera’s KIF6 diagnostic test in Abbott’s m2000 instrument. The KIF6 test is aimed at identifying an individual’s risk of coronary heart disease (CHD) and response to statin therapy. Earlier, in June 2010, Celera received CE Mark approval for its real-time PCR (polymerase chain reaction) test to detect a variant in the KIF6 gene. While Celera will manufacture the KIF6 test kits, Abbott will be responsible for its distribution in Europe and other regions recognizing the CE Mark. However, financial terms of the deal were not disclosed. We believe immense potential lies in the detection of CHD as it has been observed that a variant of the KIF6 gene is related to about 55% increased ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/23/cra-celera-corpoation-and-abbott-laboratories-sign-deal/52551/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRA) CRA International Incorporated &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/08/22/cra-cra-international-incorporated-bear-of-the-day/48964</link>
		<comments>http://www.stockbloghub.com/2010/08/22/cra-cra-international-incorporated-bear-of-the-day/48964#comments</comments>
		<pubDate>Mon, 23 Aug 2010 06:49:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48964</guid>
		<description><![CDATA[CRA International&#8217;s (CRA) second-quarter earnings were modestly ahead of the Zacks Consensus Estimate primarily owing to the uptick in utilization rate backed by successful restructuring actions. Although litigation and management consulting related areas were reasonably active, clients cautious aggregate spending and a decline in organic revenue are expected to limit the company s growth. Overall, near-term visibility remains unclear, given the current volatile market trends. Despite showing some improvement, litigation trend remains sluggish. Finally, despite the recent pick-up in activity, the Middle East business remains uncertain. Going forward, we remain skeptical about the sustainability of the growth momentum seen in the second quarter. Hence, we downgrade the stock from Neutral to Underperform. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/cra-cra-international-incorporated-bear-of-the-day/48964/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRA) Fannie Mae, Freddie Mac and the Federal Housing Authority Problems</title>
		<link>http://www.stockbloghub.com/2010/08/11/cra-fannie-mae-freddie-mac-and-the-federal-housing-authority-problems/47418</link>
		<comments>http://www.stockbloghub.com/2010/08/11/cra-fannie-mae-freddie-mac-and-the-federal-housing-authority-problems/47418#comments</comments>
		<pubDate>Wed, 11 Aug 2010 14:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Housing]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47418</guid>
		<description><![CDATA[The ultimate indication of a mortgage that has gone bad is when the lender forecloses and ends up owning the property. The graph below (from http://www.calculatedriskblog.com/) shows the number of properties that are in &#8220;Real Estate Owned&#8221; status (REO) by Fannie Mae (FNMA), Freddie Mac, the Federal Housing Authority and owned by the owners of the private-label mortgage-backed securities that were created by the likes of Merrill Lynch (now part of Bank of America, BAC) and its now defunct brethren Bear Stearns (now owned by J.P. Morgan, JPM) and Lehman Brothers. The graph speaks volumes about the housing bubble and its aftermath. The first thing to note by way of background is that the private-label paper creation pretty much came to an end in 2007 when the housing market first started to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/11/cra-fannie-mae-freddie-mac-and-the-federal-housing-authority-problems/47418/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAC) Bank of America Shines in Low-Income Lending</title>
		<link>http://www.stockbloghub.com/2010/08/07/bac-bank-of-america-shines-in-low-income-lending/47079</link>
		<comments>http://www.stockbloghub.com/2010/08/07/bac-bank-of-america-shines-in-low-income-lending/47079#comments</comments>
		<pubDate>Sat, 07 Aug 2010 17:34:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Money Center Banks]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47079</guid>
		<description><![CDATA[Bank of America Corp. (BAC) said on Thursday that it has gained an “outstanding” rating from the Office of Comptroller of the Currency for fulfilling or going beyond the requirements of affordable housing, small business lending and many other areas of underserved communities. The latest rating marks BofA’s seventh consecutive achievement of outstanding rating. The current rating follows the Office of Comptroller of the Currency’s most recent exam under the 1977 Community Reinvestment Act (CRA). The federal authorities periodically conduct such exams to evaluate lenders to underserved communities. Under the exam, BofA’s performance achieved the highest rating on the test categories of lending, services and investments. During the performance period, BofA was rated in 306 geographic assessment areas within 32 states and the District of Columbia. Including mortgage, small business ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/07/bac-bank-of-america-shines-in-low-income-lending/47079/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRA) Celera Corporation&#8217;s Revenues Dip</title>
		<link>http://www.stockbloghub.com/2010/03/04/cra-celera-corporations-revenues-dip/29711</link>
		<comments>http://www.stockbloghub.com/2010/03/04/cra-celera-corporations-revenues-dip/29711#comments</comments>
		<pubDate>Thu, 04 Mar 2010 16:52:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29711</guid>
		<description><![CDATA[Celera Corporation (CRA) reported fourth-quarter fiscal 2009 (ended Dec 26, 2009) earnings of 2 cents per share (excluding special items) compared to the Zacks Consensus Estimate of a net loss of 4 cents. The company earned 3 cents (excluding special items) in the year-ago quarter. Net revenues in the reported quarter came in at $40 million as against $47.3 million in the year-ago quarter, down approximately 15.4%. Segment-wise, revenues from lab services fell approximately 25% to $22 million compared to $29.2 million in the year-ago quarter, primarily because of lower reimbursement rates and lower sample volume. Revenues from products climbed 1% year-over-year to $11.3 million. Corporate revenues, which fell 3% year-over-year, accounted for the balance. Research and Development spending in the reported quarter decreased to $6.5 million from $7.6 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/04/cra-celera-corporations-revenues-dip/29711/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRA) Celera Corporation Posts Break-Even Earnings</title>
		<link>http://www.stockbloghub.com/2009/11/08/cra-celera-corporation-posts-break-even-earnings/19888</link>
		<comments>http://www.stockbloghub.com/2009/11/08/cra-celera-corporation-posts-break-even-earnings/19888#comments</comments>
		<pubDate>Sun, 08 Nov 2009 23:34:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[Cepheid]]></category>
		<category><![CDATA[CPHD]]></category>
		<category><![CDATA[CRA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19888</guid>
		<description><![CDATA[Celera Corp. (CRA) reported break-even earnings in the third-quarter, compared to the Zacks Consensus Estimate of a loss of 6 cents. The company earned a cent in the year-ago quarter. Net revenues for the quarter came in at $40 million as against $45.8 million in the year-ago quarter. Segment wise revenues from lab services were $24.2 million compared to $30.1 million in the year-ago quarter, primarily because of lower reimbursement rates. Revenues from products came in at $10.0 million compared to $10.5 million in the prior year quarter. Revenues for the quarter were primarily from sales of Celera-manufactured products and royalties from sales of RealTime assays used on the m2000 system from Abbott Molecular, a subsidiary of Abbott Laboratories (ABT). Corporate revenues for the quarter came in at $5.8 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/08/cra-celera-corporation-posts-break-even-earnings/19888/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Biotech Industry &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2009/06/01/mygn-biotech-industry-zacks-analyst-interviews/7669</link>
		<comments>http://www.stockbloghub.com/2009/06/01/mygn-biotech-industry-zacks-analyst-interviews/7669#comments</comments>
		<pubDate>Mon, 01 Jun 2009 23:05:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>
		<category><![CDATA[DCGN]]></category>
		<category><![CDATA[deCODE genetics Inc.]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=7669</guid>
		<description><![CDATA[OVERVIEW The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies), while the Dow Jones Biotech Index declined 3% (which includes 33 companies). At the same time, both the NASDAQ Composite and S&#38;P 500 have achieved positive returns. NASDAQ has made a gain of 11% as of 5/26/09 and the S&#38;P 500 has gained 0.8%, while the Dow Jones Industrials reached a negative 3.5% return. This constitutes a sharp contrast with last year when the Biotech industry as a whole achieved much better performance than the market. In 2008, all three biotech ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/01/mygn-biotech-industry-zacks-analyst-interviews/7669/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WYE) Biotech Industry &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/03/13/wye-biotech-industry-industry-outlook/4310</link>
		<comments>http://www.stockbloghub.com/2009/03/13/wye-biotech-industry-industry-outlook/4310#comments</comments>
		<pubDate>Fri, 13 Mar 2009 22:00:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>
		<category><![CDATA[DCGN]]></category>
		<category><![CDATA[deCODE genetics Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Incorporated]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=4310</guid>
		<description><![CDATA[OVERVIEW The financial market and the economic landscape in the U.S. have not changed much since the beginning of the year. And we believe the status quo will last for a while at least in 2009. Large biotech companies are doing OK since they have strong balance sheets to weather the current market turmoil and can generate revenue from product sales. Investors in large biotechnology companies worth more than $1 billion have preserved much of their wealth. Smaller biotech companies, particularly those still in development stage, meanwhile, are under severe strain as the global economic slump cuts into sales and their ability to raise fresh cash to fund research. As we expected, the M&#38;A spree has continued in the first three months of this year. Following the acquisition of Wyeth ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/03/13/wye-biotech-industry-industry-outlook/4310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRA) Celera Corporation &#8211; consensus estimates are relatively through the roof</title>
		<link>http://www.stockbloghub.com/2009/01/07/celera-corporation-consensus-estimates-are-relatively-through-the-roof/2033</link>
		<comments>http://www.stockbloghub.com/2009/01/07/celera-corporation-consensus-estimates-are-relatively-through-the-roof/2033#comments</comments>
		<pubDate>Wed, 07 Jan 2009 20:29:58 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2033</guid>
		<description><![CDATA[Celera Corp. (CRA) is showing phenomenal growth over the next few years as shares continue to set higher highs. Company Description Celera Corp. is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and optimize patient management. The company also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Modest Earnings&#8230;For Now On Oct 28 Celera reported third-quarter results for calendar 2008 that included net revenues of $45.8 million, up from just $16.1 in the same quarter last year. All of the revenue growth was due ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/01/07/celera-corporation-consensus-estimates-are-relatively-through-the-roof/2033/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

